HSRAANZ Podcast

HSRAANZ Interview with Professor Dorothy Keefe, CEO of Cancer Australia

October 02, 2020 Sarah Green
HSRAANZ Podcast
HSRAANZ Interview with Professor Dorothy Keefe, CEO of Cancer Australia
Chapters
00:01:15
Please tell us about your career and clinical and research interests.
00:03:23
How is COVID-19 challenging traditional cancer research and care?
00:07:44
How are virtual multi-disciplinary team meetings working?
00:08:54
What is the role of Cancer Australia in evaluating new approaches to cancer care?
00:13:02
Tell us about the role of Hospital Oncology in the Home?
00:14:55
What are some of the HSR questions that are needed?
00:18:15
What do you see as the role for consumers in shaping research and its priorities?
00:21:16
In the context of evaluating cancer care what would you ask research funders for?
00:23:46
What do you see as the benefits of communities of practice like the HSRAANZ in particular in times of research funding uncertainty and job insecurity?
HSRAANZ Podcast
HSRAANZ Interview with Professor Dorothy Keefe, CEO of Cancer Australia
Oct 02, 2020
Sarah Green

Our interviews have been focusing on “HSR during COVID-19” - the health systems response required to manage the pandemic and its aftermath and how we can minimize the collateral damage and even implement pandemic driven improvements.  Our guest today is Professor Dorothy Keefe.  Professor Keefe is the CEO of Cancer Australia, and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist, and Professor of Cancer Medicine. Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer, and more broadly, Medical Leadership and Health Reform, and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients.

Show Notes Chapter Markers

Our interviews have been focusing on “HSR during COVID-19” - the health systems response required to manage the pandemic and its aftermath and how we can minimize the collateral damage and even implement pandemic driven improvements.  Our guest today is Professor Dorothy Keefe.  Professor Keefe is the CEO of Cancer Australia, and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist, and Professor of Cancer Medicine. Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer, and more broadly, Medical Leadership and Health Reform, and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients.

Please tell us about your career and clinical and research interests.
How is COVID-19 challenging traditional cancer research and care?
How are virtual multi-disciplinary team meetings working?
What is the role of Cancer Australia in evaluating new approaches to cancer care?
Tell us about the role of Hospital Oncology in the Home?
What are some of the HSR questions that are needed?
What do you see as the role for consumers in shaping research and its priorities?
In the context of evaluating cancer care what would you ask research funders for?
What do you see as the benefits of communities of practice like the HSRAANZ in particular in times of research funding uncertainty and job insecurity?